MetaCap

Eli Lilly and Company (LLY)

NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1,347.11-4.01 (-0.30%)

At close: Nov 20, 4:02 PM ET · Delayed 15 min

LLY stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$30.81
Dividend yield
0.50% ($6.69)
Ex-dividend date
Nov 13, 2026
52-week range
850.51 – 1,475.25
Day range
1,341.77 – 1,372.05
Volume / Avg
3.54M / 2.60M
Beta
—

52-week range

$850.51$1,475.25

LLY stock today

Shares of Eli Lilly (LLY) finished lower on Nov 20 at $1,347.11, a drop of 0.30% or $4.01 per share, versus the S&P 500's 3.70% decline. Shares are 8.7% below their 52-week high of $1,475.25, set on Nov 16, 2026 and 58.4% above the 52-week low of $850.51, in the middle of the past year's range. LLY is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 27.1%.

At 43.7x trailing earnings, Eli Lilly trades above the peer-group median of 38.8x. Its forward P/E of 26.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Eli Lilly pays an annual dividend of $6.69 per share, a 0.50% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Eli Lilly

Company profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. David A. Ricks
Headquarters
Indianapolis, IN
Employees
50,000
Website
lilly.com

Financial highlights

Full financials

In fiscal 2025, Eli Lilly generated $65.18 billion in revenue, up 44.7% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $20.64 billion (+94.9% year over year), for a net margin of 31.7% versus a median of 21.9% in the prior 5 years. Gross margin was 83.0% (up from 81.3%).

Eli Lilly annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$65.18B$45.04B$34.12B$28.54B$28.32B
Growth+44.70%+32.00%+19.56%+0.79%+15.40%
Net income$20.64B$10.59B$5.24B$6.24B$5.58B
EPS (diluted)$22.95$11.71$5.80$6.90$6.12

Analyst forecast

Forecast

Consensus (31 analysts)

buy

Avg. price target

$1,468.57+9.02%

  • Strong buy 5
  • Buy 20
  • Hold 4
  • Sell 1
  • Strong sell 1

Target range

Low $940.00High $1,700.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$7.22 vs $5.38
Surprise
+34.20%

Dividends

Dividend history
Annual dividend
$6.69
Last payment
$1.73
Ex-dividend date
Nov 13, 2026

LLY news

All LLY news

Eli Lilly peers

Health Care sector
LLY peer companies
CompanyPrice% ChgMarket capCompare
JNJJohnson & Johnson270.47+1.25%$651.11Bvs LLY
ABBVAbbVie Inc.286.20+0.94%$505.89Bvs LLY
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs LLY
NVSNovartis AG150.47-0.50%$284.18Bvs LLY
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs LLY
ABTAbbott Laboratories103.00-0.84%$178.39Bvs LLY
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs LLY
PFEPfizer Inc.27.40-0.51%$156.18Bvs LLY

Indexes, lists and sector

Eli Lilly stock FAQ

What is Eli Lilly's stock price today?

LLY last traded at $1,347.11 as of Nov 20, 4:02 PM EST, down 0.30% on the day. Prices are delayed at least 15 minutes.

Does Eli Lilly pay a dividend?

Yes. Eli Lilly pays $6.69 per share annually, a 0.50% yield. The most recent dividend of $1.73 had an ex-dividend date of Nov 13, 2026.

What is LLY's P/E ratio?

LLY trades at a trailing P/E ratio of 43.72 and a forward P/E of 26.48, compared with a median of 38.8 for its closest peers.

Is Eli Lilly in the S&P 500?

Yes. Eli Lilly (LLY) is a constituent of the S&P 500 index.

Who is Eli Lilly's CEO?

Mr. David A. Ricks is the chief executive officer of Eli Lilly and Company, which has about 50,000 employees.

Has LLY ever split its stock?

Yes. The most recent LLY stock split was a 2-for-1 split on Oct 16, 1997, one of 4 splits on record.

What is the LLY 52-week high?

The 52-week high for LLY is $1,475.25 and the 52-week low is $850.51. The stock is currently 8.7% below its high.

Compare LLY